Histamine: Clinical Trials

9 trials of Histamine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 withdrawn, 2 completed, 2 unknown, 1 not yet recruiting. 9 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 29Withdrawn 3, Completed 2, Unknown 2, Not yet recruiting 1, Recruiting 1
Phase 12Unknown 1, Withdrawn 1

Follow Histamine: new trials by email Literature Review of Histamine trials Research Report on Histamine

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing, Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge, Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge - Drug Allergy, Cephalosporin Allergy
Phase 2RecruitingMassachusetts General Hospital3002025-05-052026-11-12
Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer
Histamine Dihydrochloride (HDC), Interleukin-2 (IL-2) - Pancreatic Cancer, Surgery
Phase 2Not yet recruitingSahlgrenska University Hospital502024-04-012023-11-22
Histaminergic Basis of Fatigue in Multiple Sclerosis
L-Histidine, Placebo, Lodosyn - Multiple Sclerosis
Phase 2WithdrawnUniversity of Miami2022-01-012021-07-29
A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)
Cohort 1, Ceplene® and Proleukin®, Cohort 2, Ceplene® and Proleukin®, Cohort 3, Ceplene® and Proleukin® - Leukemia, Myelomonocytic, Chronic
Phase 1 / Phase 2UnknownVastra Gotaland Region152017-02-152017-12-19
Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)
Hyaluronidase, Histamine, Saline - Allergic Skin Reaction
Phase 2CompletedAmphastar Pharmaceuticals, Inc.2532012-09-012017-01-20
Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes
Ceplene®, IL-2, Azacitidine, Azacitidine - Myelodysplastic Syndromes
Phase 1 / Phase 2WithdrawnGroupe Francophone des Myelodysplasies2011-03-012014-03-20
Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis.
Live Hookworm Larvae, Histamine - Multiple Sclerosis
Phase 2WithdrawnUniversity of Nottingham2008-02-012012-06-14
An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber
Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate, Histamine - Rhinitis, Allergic, Seasonal
Phase 2CompletedDynavax Technologies Corporation2712007-09-012019-04-16
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer
aldesleukin, histamine dihydrochloride - Kidney Cancer
Phase 2UnknownThe Christie NHS Foundation Trust1999-06-012013-09-20

Conditions studied

Hypersensitivity (3)  ·  Multiple Sclerosis (2)  ·  Anaphylaxis (1)  ·  Carcinoma, Renal Cell (1)  ·  Drug Hypersensitivity (1)  ·  Fatigue (1)  ·  Kidney Neoplasms (1)  ·  Leukemia, Myelomonocytic, Chronic (1)  ·  Myelodysplastic Syndromes (1)  ·  Neoplasm Metastasis (1)  ·  Pancreatic Neoplasms (1)  ·  Rhinitis, Allergic (1)  ·  Rhinitis, Allergic, Seasonal (1)

Sponsors

Amphastar Pharmaceuticals, Inc. (1)  ·  Dynavax Technologies Corporation (1)  ·  Groupe Francophone des Myelodysplasies (1)  ·  Massachusetts General Hospital (1)  ·  Sahlgrenska University Hospital (1)  ·  The Christie NHS Foundation Trust (1)  ·  University of Miami (1)  ·  University of Nottingham (1)  ·  Vastra Gotaland Region (1)

Countries

United States (3)  ·  United Kingdom (2)  ·  Canada (1)  ·  France (1)  ·  Sweden (1)

Top investigators

Andreas Muth (1)  ·  Cris Constantinescu, MD PhD (1)  ·  David A Khan, MD (1)  ·  Eduardo Martins, MD, DPhil (1)  ·  Kimberly G Blumenthal, MD, MSc (1)  ·  Kottil Rammohan, MD (1)  ·  Mark R. Middleton, MD, PhD, MBChB, MRCP (1)  ·  Pierre Fenaux, MD (1)  ·  Selina Su, MPH (1)

Results publications

PMID 20412135

NIH funding

U01AI184071 (1)